TCR-independent activation of T cells
View Patent ↗A method for TCR-independent T cell activation which comprises the co-ligation of CD28 and CD81.
1. A method for TCR-independent T cell activation which comprises the co-ligation of CD28 and CD81, wherein co-ligation is performed with monoclonal antibodies, wherein the monoclonal antibodies consist of a monoclonal anti-CD28 antibody and a monoclonal anti-CD81 antibody.
2. A method according to claim 1 , wherein one or more of the monoclonal antibodies have a human constant region.
3. A method according to claim 1 , which is carried out in vivo.
4. A method according to claim 1 , which is carried out in vitro.
5. A method according to claim 3 , wherein CD28 is ligated using a soluble phase anti-CD28 monoclonal antibody and CD81 is ligated using a solid-phase anti-CD81 monoclonal antibody.
6. A method according to claim 1 for the TCR-independent activation of αβ3 T cells.
7. A method according to claim 1 , for the TCR-independent activation of naïve T cells.
8. A method according to claim 1 , wherein the T cells are activated to switch type 1 cells to type 2 cells.
9. A method according to claim 1 , where the T cells are activated to produce a Th2 or Tc2 response.
10. A method according to claim 1 , wherein the T cells to be activated are CD4+ T cells.
11. A method according to claim 1 , for the activation of T cells that have already differentiated into type 2 cells.
12. A method according to claim 1 , for the activation of human T cells.